Search Result

Results for "

MAO

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Monoamine Oxidase (176) 5-HT Receptor (6) Adenosine Receptor (2) Adrenergic Receptor (3) Amyloid-β (6) Antibiotic (2) Apoptosis (8) Autophagy (3) Bacterial (1) Bcl-2 Family (1) Carbonic Anhydrase (1) Caspase (1) Cholinesterase (ChE) (27) COMT (8) Cytochrome P450 (4) Dopamine Transporter (2) Dopamine β-hydroxylase (3) Drug Metabolite (1) DYRK (1) EGFR (1) Endogenous Metabolite (3) Enterovirus (2) ERK (1) Estrogen Receptor/ERR (1) Guanylate Cyclase (2) HDAC (3) HIF/HIF Prolyl-Hydroxylase (1) Histone Demethylase (15) HSP (2) HSV (1) IAP (1) iGluR (1) Imidazoline Receptor (3) Influenza Virus (2) Isotope-Labeled Compounds (4) mGluR (2) Microtubule/Tubulin (2) NO Synthase (2) PKC (2) Reactive Oxygen Species (2) Reverse Transcriptase (2) Tau Protein (1) Telomerase (2) α-synuclein (1)
By Research Areas:	Cancer (38) Cardiovascular Disease (10) Endocrinology (3) Infection (9) Inflammation/Immunology (10) Metabolic Disease (5) Neurological Disease (155)
Click Chemistry:	Alkynes (16)

205

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

MAO-B-IN-18	Monoamine Oxidase	Neurological Disease
MAO-B-IN-18 is a potent and selective MAO B inhibitor with IC₅₀s of 52 nM and 14 μM for hMAO B and hMAO A, respectively. MAO-B-IN-18 enables promising cytoprotective effects against hydrogen peroxide insults in neuroblastoma and astrocytes cultures .

MAO-B-IN-25	Monoamine Oxidase	Neurological Disease
MAO-B-IN-25 (compound 92) is a selective *MAO-B* inhibitor with IC₅₀s of 0.5 nM and 240 nM for MAO-A and MAO-B, respectively .

MAO A/HDAC-IN-1	Monoamine Oxidase HDAC	Cancer
MAO A/HDAC-IN-1 is a dual?inhibitor?of *monoamine oxidase A (MAO* A) and HDAC*. MAO* A/HDAC-IN-1 can be used for glioma research . MAO A/HDAC-IN-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

MAO-IN-3	Monoamine Oxidase	Cancer
MAO-IN-3 (Compound 5) is a reversible and competitive *MAO* inhibitor (K_i: 0.6 and 0.2 μM for MAO A and MAO B). MAO-IN-3 inhibits LN-229 glioblastoma cell proliferation with an IC₅₀ of 0.8 μM. MAO-IN-3 can be used for cancer research .

MAO-IN-4	Monoamine Oxidase	Neurological Disease
MAO-IN-4 (Compound 2l) is a monoamine oxidase (MAO) inhibitor, with IC₅₀ values of 0.07 and 0.75 μM for MAO-A and MAO-B Enzymes, respectively. MAO-IN-4 can be used for the research of depression and Parkinson’s disease (PD) .

MAO-IN-1	Monoamine Oxidase	Neurological Disease
MAO-IN-1 is a monoamine oxidase B (MAO B) inhibitor with an IC₅₀ of 20 nM.

MAO-B-IN-30	Monoamine Oxidase	Neurological Disease Inflammation/Immunology
MAO-B-IN-30 (compound IS7) is a potent, selective and cross the blood-brain barrier *MAO-B* inhibitor with IC₅₀ values of 19.176, 0.082 µM for MAO-A and MAO-B, respectively. MAO-B-IN-30 shows antiproliferative activity and non-cytotoxic. MAO-B-IN-30 reduces TNF-alpha, IL-6, NF-kB levels. MAO-B-IN-30 has the potential for the research of Parkinson's disease .

MAO-B-IN-27	Monoamine Oxidase	Neurological Disease
MAO-B-IN-27 (Compound 12c) is a monoamine oxidase B (MAO-B) inhibitor. MAO-B-IN-27 has potent and selective MAO-B inhibitory effect for hMAO-B with an IC₅₀ values of 8.9 nM. MAO-B-IN-27 can be used for the research of parkinson's disease (PD) .

MAO-A/B-IN-2	Monoamine Oxidase	Neurological Disease
MAO-A/B-IN-2 (compound 30) is a *MAO-A/B* inhibitor with IC₅₀ values of 17.8 and 15.8 μM for *MAO-A* and *MAO-B, respectively. MAO*-A/B-IN-2 can be used in the study of neurological disorders .

MAO-IN-5	Monoamine Oxidase	Neurological Disease
MAO-IN-5 (Compound ZINC000016952895) is a monoamine oxidase (MAO) inhibitor. According to the prediction of Swiss ADME, MAO-IN-5 can inhibit the CYP enzyme family, has blood-brain barrier (BBB) permeability, and has a high gastrointestinal absorption rate. MAO-IN-5 can be used in the study of neurological diseases .

MAO-B-IN-4	Monoamine Oxidase	Neurological Disease
MAO-B-IN-4 (Compound 26) is an orally active and reversible *MAO-B* inhibitor with an IC₅₀ of 9 nM. MAO-B-IN-4 has good metabolic stability, safety profile and brain permeability. MAO-B-IN-4 shows antidepressant activity in rats and mice. MAO-B-IN-4 can be used in studies related to Alzheimer's disease .

MAO-B-IN-8	Monoamine Oxidase	Neurological Disease
MAO-B-IN-8 is a potent reversible *MAO-B* inhibitor and an inhibitor of microglial production of neuroinflammatory mediator. MAO-B-IN-8 can be used for neurodegenerative disease research .

MAO-B-IN-6	Monoamine Oxidase	Neurological Disease
MAO-B-IN-6 is a potent, selective and orally active *MAO-B* inhibitor with an IC₅₀ of 0.019 µM. MAO-B-IN-6 shows more efficacious than Safinamide in vitro and in vivo. MAO-B-IN-6 has the potential for the research of parkinson's disease (PD) .

MAO-B-IN-20	Monoamine Oxidase	Neurological Disease
MAO-B-IN-20 (Compound C14) is a potent *MAO-B* inhibitor with an IC₅₀ of 0.037 μM. MAO-B-IN-20 displays good metabolic stability and brain-blood barrier permeability. MAO-B-IN-20 can be used for the research of Parkinson's disease .

MAO-B-IN-29	Monoamine Oxidase	Neurological Disease
MAO-B-IN-29 (compound 9a) is a inhibitor against *MAO-B* activity .

MAO-B-IN-14	Monoamine Oxidase	Neurological Disease
MAO-B-IN-14 (Compound 9) is a potent and selective monoamine oxidase-B (MAO-B) inhibitor with an IC₅₀ of 0.95 μM and a K_i of 0.55 μM against human MAO-B.

MAO-B-IN-3	Monoamine Oxidase 5-HT Receptor	Neurological Disease
MAO-B-IN-3 is a reversible and selective *MAO-B* inhibitor (IC₅₀=96 nM). MAO-B-IN-3 also binds to 5-HT₆R with K_i value of 696 nM. MAO-B-IN-3 can be used for research of in Alzheimer's disease .

MAO-B-IN-13	Monoamine Oxidase	Neurological Disease
MAO-B-IN-13 (compound 12a) is a highly potent, reversible and blood-brain barrier (BBB) penetrant *MAO-B* inhibitor with an IC₅₀ value of 10 nM. MAO-B-IN-13 has neuroprotective and antioxidant activity. MAO-B-IN-13 can be used for researching Parkinson’s disease .

MAO-B-IN-5	Monoamine Oxidase	Neurological Disease
MAO-B-IN-5 is a potent, selective and orally active *MAO-B* inhibitor with an IC₅₀ of 0.204 µM. MAO-B-IN-5 has the potential for the research of Parkinson's disease (PD) .

MAO-B-IN-12	Monoamine Oxidase	Neurological Disease
MAO-B-IN-12 (Compound 16c) is a potent monoamine oxidase B (MAO-B) inhibitor with an IC₅₀ of 1.3 μM. MAO-B-IN-12 shows a neuroprotective activity .

MAO-B-IN-11	Monoamine Oxidase	Neurological Disease
MAO-B-IN-11 (Compound 8c) is a potent monoamine oxidase B (MAO-B) inhibitor with an IC₅₀ of 1.3 μM. MAO-B-IN-11 shows a neuroprotective activity .

MAO-B-IN-19	Monoamine Oxidase	Neurological Disease Inflammation/Immunology
MAO-B-IN-19 is a selective *MAO-B* inhibitor with an IC₅₀ of 0.67 μM. MAO-B-IN-19 shows neuroprotective and anti-inflammatory properties .

MAO-B-IN-7	Monoamine Oxidase Cholinesterase (ChE) Reactive Oxygen Species	Neurological Disease Inflammation/Immunology
MAO-B-IN-7 is a potent and blood-brain barrier permeable *MAO-B* and AChE inhibitor with IC₅₀s of 41 nM, 87 nM and 0.3 μM for human AChE, electric eel AChE and MAO-B, respectively. MAO-B-IN-7 can effectively alleviate oxidative stress and neuroinflammatory damage .

MAO-B-IN-24	Monoamine Oxidase Cholinesterase (ChE)	Cancer
MAO-B-IN-24 (compound 11h) is a selective, reversible, competitive inhibitor of MAO-B (IC₅₀: 1.60 μM). MAO-B-IN-24 also inhibited MAO-A (22.42 μM); at 10 μM concentration, it also reduced AChE and BChE activities to 54.58% and 88.43% .

MAO-B-IN-17	Monoamine Oxidase	Neurological Disease
MAO-B-IN-17 is a selective monoamine oxidase B (MAO-B) inhibitor with the IC₅₀ value of 5.08 μM. MAO-B-IN-17 can be used in Parkinson’s disease research .

MAO-B-IN-16	Monoamine Oxidase	Neurological Disease
MAO-B-IN-16 is a selective monoamine oxidase B (MAO-B) inhibitor, with an IC₅₀ of 1.55 µM. MAO-B-IN-16 can be used in the study of central nervous disorders, such as parkinson's disease .

MAO-B-IN-26	Monoamine Oxidase Autophagy Apoptosis Cholinesterase (ChE)	Neurological Disease
MAO-B-IN-26 (Compound IC9) is a *MAO-B* and acetylcholinesterase inhibitor. MAO-B-IN-26 protects SH?SY5Y cells against Aβ induced cytotoxicity, morphological changes, ROS generation and membrane damage. MAO-B-IN-26 also inhibits Aβ induced autophagy and apoptosis. MAO-B-IN-26 can be used as a neuroprotective agent against Alzheimer’s disease .

MAO-IN-M30 dihydrochloride	Monoamine Oxidase	Neurological Disease
MAO-IN-M30 dihydrochloride is an orally active, brain-permeable, and brain selective irreversible *MAO-A* (IC₅₀=37 nM) and *MAO-B* (IC₅₀=57 nM) inhibitor. MAO-IN-M30 dihydrochloride is a potent iron chelator and radical scavenger. MAO-IN-M30 dihydrochloride has a neuroprotective effect against Dexamethasone-induced brain cell apoptosis. MAO-IN-M30 dihydrochloride also exhibits neurorestorative activity in post MPTP and lactacystin models of Parkinson's disease . MAO-IN-M30 (dihydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

MAO-B-IN-15	Monoamine Oxidase	Neurological Disease
MAO-B-IN-15 is a selective *MAO-B* inhibitor (IC₅₀: 13.5 μM) that forms π-π interaction with Tyr 326 residue. MAO-B-IN-15 can be used in the research of Parkinson’s disease .

MAO-B-IN-10	Monoamine Oxidase Amyloid-β	Neurological Disease
MAO-B-IN-10 (compound 4f) is a potent, selective, BBB-penetrated *MAO-B* (monoamine oxidase-B) inhibitor, with IC₅₀ of 5.3 μM. MAO-B-IN-10 can inhibit (58.2%) and disaggregate (43.3%) self-mediated Aβ (amyloid β) aggregation. MAO-B-IN-10 can be use for Alzheimer’s disease research .

MAO-B-IN-2	Monoamine Oxidase	Neurological Disease
MAO-B-IN-2 is a selective and competitive inhibitor of MAO-B and BChE with IC₅₀ values of 0.51 and 7.00 μM, respectively.

MAO-B-IN-22	Monoamine Oxidase	Neurological Disease
MAO-B-IN-22 (compound 6h) is a potent *MAO-B* inhibitor with an IC₅₀ of 0.014 μM. MAO-B-IN-22 has high antioxidant activity, good metal chelating ability, proper BBB permeability and significant neuroprotective effect .

MAO-A inhibitor 2	Monoamine Oxidase	Neurological Disease
MAO-A inhibitor 2 (compound HT4) is a monoamine oxidase A (MAO-A) inhibitor with an IC₅₀ of 14.3 µM. MAO-A inhibitor 2 shows a less effect on MAO-B (IC₅₀ of 106 µM) and shows almost ineffective on xanthine oxidase (XO). MAO-A inhibitor 2 can be used for the neurodegenerative disorders and oxidative stress research .

MAO-B-IN-21	Monoamine Oxidase	Neurological Disease Inflammation/Immunology
MAO-B-IN-21 is an excellent *MAO-B* inhibitor with antioxidant activity and anti-Aβ aggregation activity. MAO-B-IN-21 also exhibits metal-ion chelating ability, anti-neuroinflammation (NO, TNF-α), neuroprotective activity and BBB permeability. MAO-B-IN-21 significantly improves the memory and cognitive impairment in Aβ1-42 induced Alzheimer's disease mice model .

MAO-B-IN-23	Monoamine Oxidase	Neurological Disease
MAO-B-IN-23 (Compound 11f) is a reversible and competitive *MAO-B* inhibitor (IC₅₀: 1.44 μM, K_i: 0.51 μM) .

MAO-B-IN-31	Monoamine Oxidase α-synuclein Tau Protein	Neurological Disease
MAO-B-IN-31 (Compound 30) is an effective and selective inhibitor of monoamine oxidase B (monoamine oxidase B). The IC₅₀ value is 41 nM. MAO-B-IN-31 also inhibits α-syn and tau aggregation. MAO-B-IN-31 has neuroprotective activity .

MAO-A inhibitor 1	Monoamine Oxidase	Cancer
MAO-A inhibitor 1 (compound VIII) is a *MAO-A* inhibitor, with an IC₅₀ of 100 μM .

MAO-B-IN-9	Monoamine Oxidase Amyloid-β	Neurological Disease
MAO-B-IN-9 (compound 16) is a potent, selective, BBB-penetrated, irreversible and time-dependent *MAO-B* (monoamine oxidase B) inhibitor, with an IC₅₀ of 0.18 μM. MAO-B-IN-9 prevents Aβ_1-42-induced neuronal cell death. MAO-B-IN-9 shows neuroprotective effects, which may be the result of its Aβ_1-42 anti-aggregation effects . MAO-B-IN-9 is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

MAO-B-IN-28	Monoamine Oxidase	Neurological Disease
MAO-B-IN-28 (compound 10e) is a potent hMAO-B inhibitor with an IC₅₀ of 1.9±0.5 nM. MAO-B-IN-28 can be used as a candidate for neurodegenerative diseases research .

MAO-B-IN-1	Monoamine Oxidase	Neurological Disease
MAO-B-IN-1 is an inhibitor of monoamine oxidase B, used for the research of neurological diseases.

MAO A/HSP90-IN-1	Monoamine Oxidase HSP	Cancer
MAO A/HSP90-IN-1 (4-b) is a MAO A/HSP90 dual inhibitor with IC₅₀ value of 1.77 μM and 0.019 μM in Glioblastoma (GBM) GL26 cells and HSP90α, respectively. MAO A/HSP90-IN-1 (4-b) can inhibit MAO A activity, HSP90 binding and the expression of HER2 and phospho-Akt to inhibit the growth of GBM, they also reduce PD-L1 expression, which inhibits T cell activation. MAO A/HSP90-IN-1 (4-b) have potential to inhibit tumor immune escape. MAO A/HSP90-IN-1 (4-b) can be used for brain tumor-related diseases research .

MAO A/HSP90-IN-2	Monoamine Oxidase HSP	Cancer
MAO A/HSP90-IN-2 (compound 4-C) is a dual inhibitor of HSP90and MAO A with the IC₅₀ values of 0.016 and 4.58 μM, respectively. MAO A/HSP90-IN-2 increases HSP70 expression and reduces HER2 and phospho-Akt expression, and decreases IFN-γ induced PD-L1 expression in GL26 cells. MAO A/HSP90-IN-2 inhibits the growth of Temozolomide (HY-17364) -sensitive and -resistant GBM cells, colon cancer, leukemia, non-small cell lung and other cancers, and has potential to inhibit tumor immune escape ^[1].

MAO-A/5-HT2AR-IN-1	Monoamine Oxidase 5-HT Receptor	Neurological Disease
MAO-A/5-HT2AR-IN-1 (compound I14) is a potent *MAO-A* and 5-HT2AR dual inhibitor, with IC₅₀ values of 0.004 and 0.014 μM, respectively. MAO-A/5-HT2AR-IN-1 is a potential antidepressant agent .

MAOS	Reactive Oxygen Species	Others
MAOS is a modified Trinder’s reagent that can be used as a chromogenic probe for the determination of H₂O₂. MAOS is strongly dependent on the pH of the reaction medium .

Rosiridin	Monoamine Oxidase	Neurological Disease
Rosiridin inhibits MAO A and MAO B with potential beneficial effect in depression and senile dementia. Rosiridin shows an inhibition of 83.8% against MAO B at 10 μM (pIC₅₀=5.38) .

*AChE/MAO-IN-1*	Cholinesterase (ChE) Monoamine Oxidase Amyloid-β	Neurological Disease
AChE/MAO-IN-1 (Compound D28) is a potent AChE, *MAO-A* and *MAO-B* inhibitor with IC₅₀s of 0.0248, 0.0409 and 0.1108 μM against human AChE, MAO-B and MAO-A, respectively .

Cat. No.	Product Name	Type

HY-15923

MAOS	Fluorescent Dyes/Probes
MAOS is a modified Trinder’s reagent that can be used as a chromogenic probe for the determination of H₂O₂. MAOS is strongly dependent on the pH of the reaction medium .

HY-D0004

Azure B Azure B chloride	Dyes
Azure B is a cationic dye and the major metabolite of Methylene blue. Azure B is used in making Azure eosin stains for blood smear staining. Azure B is a high-potency, selective and reversible inhibitor of monoamine oxidases (MAO)-A, with IC₅₀s of 11 and 968 nM for recombinant human MAO-A and MAO-B, respectively. Azure B possesses significant antidepressant-like effects .

HY-14536

Methylene Blue

10+ Cited Publications

Basic Blue 9; CI-52015; Methylthioninium chloride

Chromogenic Assays

Methylene blue (Basic Blue 9) is a guanylyl cyclase (sGC), monoamine oxidase A (MAO-A) and NO synthase (NOS) inhibitor. Methylene blue is a vasopressor and is often used as a dye in several medical procedures. Methylene blue through the nitric oxide syntase/guanylate cyclase signalling pathway to reduce prepulse inhibition. Methylene blue is a REDOX cycling compound and able to cross the blood-brain barrier. Methylene blue is a Tau aggregation inhibitor. Methylene blue reduces cerebral edema, attenuated microglial activation and reduced neuroinflammation .

HY-17447AG

Tranylcypromine hydrochloride (GMP) SKF 385 hydrochloride (GMP)	Fluorescent Dye
Tranylcypromine (SKF 385) hydrochloride (GMP) is Tranylcypromine (HY-17447) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Tranylcypromine hydrochloride is a potent monoamine oxidase (MAO) inhibitor .

Cat. No.	Product Name	Type

HY-17447AG

Tranylcypromine hydrochloride (GMP) SKF 385 hydrochloride (GMP)	Biochemical Assay Reagents
Tranylcypromine (SKF 385) hydrochloride (GMP) is Tranylcypromine (HY-17447) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Tranylcypromine hydrochloride is a potent monoamine oxidase (MAO) inhibitor .

Cat. No.	Compare	Product Name	Species	Source

HY-P71521

	Rnls Protein, Mouse (His-SUMO) Rnls; Renalase; EC 1.6.3.5; Monoamine oxidase-C; MAO-C; mMAO-C	Mouse	E. coli
	The Rnls protein catalyzes the oxidation of the less abundant 1,2-dihydro-β-NAD(P) and 1,6-dihydro-β-NAD(P) to form β-NAD(P)(+). Mainly secreted by the kidneys, this enzyme circulates in the blood and plays a vital role in regulating heart function and systemic blood pressure. Rnls Protein, Mouse (His-SUMO) is the recombinant mouse-derived Rnls protein, expressed by E. coli , with N-His, N-SUMO labeled tag. The total length of Rnls Protein, Mouse (His-SUMO) is 325 a.a., with molecular weight of ~52.0 kDa.

Cat. No.	Product Name	Chemical Structure

HY-14605S

Rasagiline-13C3 mesylate
Rasagiline- ¹³C₃ ((R)-AGN1135- ¹³C₃; TVP1012- ¹³C₃) mesylateis the deuterium labeledRasagiline (mesylate)(HY-14605) . Rasagiline (R-AGN1135) mesylate is a highly potent selective irreversible mitochondrial monoamine oxidase (MAO) inhibitor with IC₅₀s of 4.43?nM and 412?nM for rat brain MAO B and A activity, respectively .

HY-101392S

Harmane-d1

Harmane-d is the deuterium labeled Harmane. Harmane, a β-Carboline alkaloid (BCA), is a potent neurotoxin that causes severe action tremors and psychiatric manifestations. Harmane shows 1000-fold selectivity for I1-Imidazoline receptor (IC50=30 nM) over α2-adrenoceptor (IC50=18 μM). Harmane is also a potent and selective inhibitor of monoamine oxidase (MAO) (IC50s=0.5 and 5 μM for human MAO A/B, respectively)[1][2][3][4].

HY-17447SA

Tranylcypromine-d5 hydrochloride

Tranylcypromine-d₅ (hydrochloride) is a deuterium labeled (rel)-Tranylcypromine hydrochloride. Tranylcypromine hydrochloride is an irreversible, nonselective monoamine oxidase (MAO) inhibitor used in the treatment of depression. Tranylcypromine hydrochloride is also a lysine-specific demethylase 1 (LSD1) inhibitor, suppresses lesion growth and improves generalized hyperalgesia in mouse with induced endometriosis[1][2].

HY-17447AS

(1S,2R)-Tranylcypromine-d5 hydrochloride

(1S,2R)-Tranylcypromine-d₅ (hydrochloride) is the deuterium labeled Tranylcypromine hydrochloride[1]. Tranylcypromine hydrochloride (SKF 385 hydrochloride) is an irreversible inhibitor of lysine-specific demethylase 1 (LSD1/BHC110) and monoamine oxidase (MAO). Tranylcypromine hydrochloride inhibits LSD1, MAO A and MAO B with IC50s of 20.7, 2.3 and 0.95 μM, respectively. Tranylcypromine hydrochloride can be used for the research of depression[2][3][4].

HY-Y0882S1

Hydroxylamine-d3 hydrochloride
Hydroxylamine-d₃ (hydrochloride) is the deuterium labeled Hydroxyamine hydrochloride[1]. Hydroxyamine hydrochloride is a selective monoamine oxidase (MAO) inhibitor used for inhibiting of platelet aggregation. Hydroxyamine hydrochloride is an intermediate of organic synthesis[2].

HY-101392S1

Harmane-d2

Harmane-d₂ is the deuterium labeled Harmane. Harmane, a β-Carboline alkaloid (BCA), is a potent neurotoxin that causes severe action tremors and psychiatric manifestations. Harmane shows 1000-fold selectivity for I1-Imidazoline receptor (IC50=30 nM) over α2-adrenoceptor (IC50=18 μM). Harmane is also a potent and selective inhibitor of monoamine oxidase (MAO) (IC50s=0.5 and 5 μM for human MAO A/B, respectively)[1][2][3][4].

HY-70057S1

Safinamide-d4-1

Safinamide-d₄-1 is deuterium labeled Safinamide. Safinamide is a potent, selective, and reversible monoamine oxidase B (MAO-B) inhibitor (IC50=0.098 µM) over MAO-A (IC50=580 µM)[1]. Safinamide also blocks sodium channels and modulates glutamate (Glu) release, showing a greater affinity at depolarized (IC50=8 µM) than at resting (IC50=262 µM) potentials. Safinamide has neuroprotective and neurorescuing effects and can be used for the study of parkinson disease, ischemia stroke etc.al[2][3].

HY-14280S

Entacapone-d10

Entacapone-d₁₀ is the deuterium labeled Entacapone. Entacapone is a potent, reversible, peripherally acting and orally active catechol-O-methyltransferase (COMT) inhibitor. Entacapone inhibits COMT from rat brain, erythrocytes and liver with IC50 values of 10 nM, 20 nM, and 160 nM, respectively. Entacapone is selective for COMT over other catecholamine metabolizing enzymes, including MAO-A, MAO-B, phenolsulphotransferase M (PST-M) and PST-P (IC50s>50 µM). Entacapone can be used for the research of Parkinson's disease[1]. Entacapone serves as a inhibitor of FTO demethylation with an IC50 of 3.5 μM, can be used for the research of metabolic disorders[2].

HY-B0534S1

Moclobemide-d4
Moclobemide-d₄ is deuterium labeled Moclobemide. Moclobemide (Ro111163) is a brain-penetrant and reversible monoamine oxidase (MAO-A) inhibitor with an IC50 of 6.061 μM for hMAO-A[1].Moclobemide up-regulates proliferation of hippocampal progenitor cells in chronically stressed mice.

HY-W015490S

1,4-Naphthoquinone-d6
1,4-Naphthoquinone-d₆ is the deuterium labeled 1,4-Naphthoquinone[1]. 1,4-Naphthoquinone is a potential pharmacophore for inhibition of both MAO (monoamine oxidase) and DNA topoisomerase activities, this latter associated with antitumor activity[2].

HY-14280S2

(E)-Entacapone-d10

(E)-Entacapone-d₁₀ is the deuterium labeled Entacapone. Entacapone is a potent, reversible, peripherally acting and orally active catechol-O-methyltransferase (COMT) inhibitor. Entacapone inhibits COMT from rat brain, erythrocytes and liver with IC50 values of 10 nM, 20 nM, and 160 nM, respectively. Entacapone is selective for COMT over other catecholamine metabolizing enzymes, including MAO-A, MAO-B, phenolsulphotransferase M (PST-M) and PST-P (IC50s>50 µM). Entacapone can be used for the research of Parkinson's disease[1]. Entacapone serves as a inhibitor of FTO demethylation with an IC50 of 3.5 μM, can be used for the research of metabolic disorders[2].

HY-14605BS

Rasagiline-13C3 mesylate racemic

Rasagiline- ¹³C₃ (mesylate racemic) is a ¹³C-labeled Rasagiline mesylate racemic. Rasagiline mesylate racemic is a highly potent selective irreversible mitochondrial monoamine oxidase (MAO) inhibitor[1]. Rasagiline-13C3 (mesylate racemic) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Cat. No.	Product Name	Application	Reactivity

HY-P82294

Monoamine Oxidase B Antibody (YA2039)

Adrenalin oxidase; MAO; brain; MAO; platelet; MAOB
WB, IHC-P Human
HY-P82728

Renalase Antibody (YA2473)

MAO C; mMAO C; Renalase; RNLS
WB, IHC-P Human, Mouse, Rat
HY-P82291

Monoamine Oxidase A Antibody (YA2036)

MAOA; Amine oxidase [flavin-containing] A; Monoamine oxidase type A; MAO-A
WB, IHC-P, ICC/IF, FC Human, Mouse, Rat

Cat. No.	Product Name		Classification

HY-131036

MAO-IN-M30 dihydrochloride		Alkynes
MAO-IN-M30 dihydrochloride is an orally active, brain-permeable, and brain selective irreversible *MAO-A* (IC₅₀=37 nM) and *MAO-B* (IC₅₀=57 nM) inhibitor. MAO-IN-M30 dihydrochloride is a potent iron chelator and radical scavenger. MAO-IN-M30 dihydrochloride has a neuroprotective effect against Dexamethasone-induced brain cell apoptosis. MAO-IN-M30 dihydrochloride also exhibits neurorestorative activity in post MPTP and lactacystin models of Parkinson's disease . MAO-IN-M30 (dihydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-10400

Ladostigil hemitartrate TV-3326 hemitartrate		Alkynes
Ladostigil (TV-3326) hemitartrate is an orally active dual inhibitor of cholinesterase and brain-selective monoamine oxidase (MAO), with IC₅₀s of 37.1 and 31.8 μM for *MAO-B* and AChE, respectively. Ladostigil hemitartrate exhibits neuroprotective, antioxidant and anti-inflammatory activities. Ladostigil hemitartrate can be used for the research of depression and Alzheimer's disease . Ladostigil (hemitartrate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-142706

MAO A/HDAC-IN-1		Alkynes
MAO A/HDAC-IN-1 is a dual?inhibitor?of *monoamine oxidase A (MAO* A) and HDAC*. MAO* A/HDAC-IN-1 can be used for glioma research . MAO A/HDAC-IN-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-146314

MAO-B-IN-9		Alkynes
MAO-B-IN-9 (compound 16) is a potent, selective, BBB-penetrated, irreversible and time-dependent *MAO-B* (monoamine oxidase B) inhibitor, with an IC₅₀ of 0.18 μM. MAO-B-IN-9 prevents Aβ_1-42-induced neuronal cell death. MAO-B-IN-9 shows neuroprotective effects, which may be the result of its Aβ_1-42 anti-aggregation effects . MAO-B-IN-9 is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-146677

*5-HT6R/MAO-B modulator 1*		Alkynes
5-HT6R/MAO-B modulator 1 (compound 48) is an antagonist of 5-HT₆R at Gs signaling and an irreversible *MAO-B* inhibitor. 5-HT6R/MAO-B modulator 1 exhibits glioprotective properties. 5-HT6R/MAO-B modulator 1 can reverse Scopolamine-induced memory deficits . 5-HT6R/MAO-B modulator 1 is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-10399

Ladostigil TV-3326		Alkynes
Ladostigil (TV-3326) is an orally active dual inhibitor of cholinesterase and brain-selective monoamine oxidase (MAO), with IC₅₀s of 37.1 and 31.8 μM for *MAO-B* and AChE, respectively. Ladostigil exhibits neuroprotective, antioxidant and anti-inflammatory activities. Ladostigil can be used for the research of depression and Alzheimer's disease . Ladostigil is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-10399A

Ladostigil hydrochloride TV-3326 hydrochloride		Alkynes
Ladostigil (TV-3326) hydrochloride is an orally active dual inhibitor of cholinesterase and brain-selective monoamine oxidase (MAO), with IC₅₀s of 37.1 and 31.8 μM for *MAO-B* and AChE, respectively. Ladostigil hydrochloride exhibits neuroprotective, antioxidant and anti-inflammatory activities. Ladostigil can be used for the research of depression and Alzheimer's disease . Ladostigil (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-121072

ASS234		Alkynes
ASS234 is a potent monoamino oxidase (MAO) inhibitor with IC₅₀s of 5.2 nM and 43 nM for MAO-A and MAO-B, respectively. ASS234 also inhibits AChE and BuChE with IC₅₀s of 350 nM and 460 nM, respectively .

HY-A0091

Pargyline hydrochloride 2 Publications Verification		Alkynes
Pargyline hydrochloride is an irreversible monoamine oxidase (MAO) inhibitor with K_is of 13 μM and 0.5 μM for *MAO-A* and *MAO-B*, respectively. Pargyline hydrochloride has antihypertensive and anticancer activities . Pargyline (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-A0091A

Pargyline 2 Publications Verification		Alkynes
Pargyline is an irreversible monoamine oxidase (MAO) inhibitor with K_is of 13 μM and 0.5 μM for *MAO-A* and *MAO-B*, respectively. Pargyline has antihypertensive and anticancer activities . Pargyline is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-14605

Rasagiline mesylate 5 Publications Verification (R)-AGN1135 mesylate; TVP1012 mesylate		Alkynes
Rasagiline (R-AGN1135) mesylate is a highly potent selective irreversible mitochondrial monoamine oxidase (MAO) inhibitor with IC₅₀s of 4.43?nM and 412?nM for rat brain MAO B and A activity, respectively . Rasagiline (mesylate) is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-14605A

Rasagiline 5 Publications Verification (R)-AGN1135; TVP1012		Alkynes
Rasagiline (R-AGN1135) is a highly potent selective irreversible mitochondrial monoamine oxidase (MAO) inhibitor with IC₅₀s of 4.43?nM and 412?nM for rat brain MAO B and A activity, respectively . Rasagiline is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-119532

Nordeprenyl Desmethylselegiline		Alkynes
Nordeprenyl is the metabolite of Deprenyl. Deprenyl is a potent, selective and irreversible inhibitor of MAO-B . Nordeprenyl is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-14605BS

Rasagiline-13C3 mesylate racemic AGN1135-¹³C₃; TVP1012-¹³C₃ racemic		Alkynes
Rasagiline- ¹³C₃ (mesylate racemic) is a ¹³C-labeled Rasagiline mesylate racemic. Rasagiline mesylate racemic is a highly potent selective irreversible mitochondrial monoamine oxidase (MAO) inhibitor[1]. Rasagiline-13C3 (mesylate racemic) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-120419

PF9601N		Alkynes
PF9601N, an monoamine oxidase B (MAO-B) inhibitor, possesses neuroprotective properties in several in vitro and in vivo models of Parkinson's disease (PD). PF9601N can be used for the research of neurodegenerative diseases mediated by excitotoxicity . PF9601N is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-145259

HDAC6-IN-3		Alkynes
HDAC6-IN-3 (Compound 14), an antiprostate cancer agent, is a potent, orally active HDAC6 inhibitor with IC₅₀s ranging from 0.02-1.54 μM for HDAC1/2/3/6/8/10. HDAC6-IN-3 is also an effective *MAO-A* (IC₅₀=0.79 μM) and LSD1 inhibitor . HDAC6-IN-3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks